Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591027 · ClinicalTrials.gov registry record · Phase 1
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
A Phase 1 study of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05591027 is a Phase 1 study of Mild Cognitive Impairment and Alzheimers Disease that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 48 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05591027, a Phase 1 study of Mild Cognitive Impairment and Alzheimers Disease, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Centella asiatica product
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05591027
The ClinicalTrials.gov registry entry for NCT05591027 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05591027 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05591027 about?
NCT05591027 is a clinical study titled "Safety and Target Engagement of Centella Asiatica in Cognitive Impairment". This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica wat...
What is the current status of trial NCT05591027?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-12-01. Estimated completion is 2026-03-31.
What conditions does trial NCT05591027 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease.
What interventions are being tested in trial NCT05591027?
The interventions under investigation include: Placebo (DRUG), Centella asiatica product (DRUG).
Who is sponsoring clinical trial NCT05591027?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05591027 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Sense4Safety Intervention
RECRUITING · Phase 1
-
CogT pSOPT Intervention Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
RECRUITING · Phase 1
-
Innate Immunity Stimulation Via TLR9 in Early AD
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.